HR 3214

Food and Drug Administration Mission Reform Act of 2011

Congress: 112 (2011–2013, Ended)
Chamber: House
Policy Area: Health
Introduced: Oct 14, 2011
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Oct 18, 2011)
Official Text: https://www.congress.gov/bill/112th-congress/house-bill/3214

Sponsor

Name: Rep. Rogers, Mike J. [R-MI-8]
Party: Republican • **State:** MI • **Chamber:** House

Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Blackburn, Marsha [R-TN-7]	R · TN		Oct 14, 2011
Rep. Bono Mack, Mary [R-CA-45]	R · CA		Oct 14, 2011
Rep. Guthrie, Brett [R-KY-2]	R · KY		Oct 14, 2011
Rep. Latta, Robert E. [R-OH-5]	R · OH		Oct 14, 2011
Rep. McMorris Rodgers, Cathy [R-WA-5]	R · WA		Oct 14, 2011
Rep. Myrick, Sue Wilkins [R-NC-9]	R · NC		Oct 14, 2011
Rep. Paulsen, Erik [R-MN-3]	R · MN		Oct 14, 2011
Rep. Shimkus, John [R-IL-19]	R · IL		Oct 14, 2011
Rep. Culberson, John Abney [R-TX-7]	R · TX		Oct 24, 2011
Rep. Rokita, Todd [R-IN-4]	R · IN		Jan 23, 2012

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 18, 2011

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
112 S 1972	Related bill	**Dec 8, 2011:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Oct 14, 2011)

Food and Drug Administration Mission Reform Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to revise the mission of the Food and Drug Administration (FDA) to include establishment of a regulatory system that: (1) advances medical innovation by incorporating modern scientific tools, standards, and approaches; (2) protects the public health and enables patients to access novel products while promoting economic growth, innovation, competitiveness, and job creation among the industries regulated by the FFDCA; (3) is based on the best available science; (4) allows for public participation and an open exchange of ideas; (5) promotes predictability, allows flexibility, and reduces uncertainty; (6) identifies and uses the most innovative and least burdensome tools for achieving regulatory ends; (7) ensures that regulations are accessible, consistent, transparent, written in plain language, and easy to understand; (8) measures, and seeks to improve, the actual results of regulatory requirements; and (9) incorporates a patient-focused benefit-risk framework that accounts for varying degrees of risk tolerance.

Actions Timeline

- **Oct 18, 2011:** Referred to the Subcommittee on Health.
- **Oct 14, 2011:** Introduced in House
- **Oct 14, 2011:** Referred to the House Committee on Energy and Commerce.

Generated by **LegiList** — https://legilist.com · Public data belongs to the public.